Portfolio concentration and sector weightings set these two popular income funds apart for investors

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call

B of A Securities analyst Tim Anderson maintains Merck & Co (NYSE:MRK) with a Buy and raises

A bipartisan group of United States lawmakers has opened national security investigations into wheth

Scotiabank analyst Louise Chen maintains Merck & Co (NYSE:MRK) with a Sector Outperform and r

US lawmakers probe Merck and AbbVie over national security and ethical risks tied to clinical trials

Stock futures are pointed lower to end the month and quarter as AI capex concerns linger

A bipartisan group of United States lawmakers has opened national security investigations into wheth

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology c

Merck extends its bullish breakout from a pennant pattern, supported by strong volume and higher swi

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations

Agreement will help state ADAP programs provide access to IDVYNSO™ (doravirine/islatravir) for eligi

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Agreement to Improve Treatment Access f

Merck (MRK) closed the most recent trading day at $128.66, moving +2.56% from the previous trading s

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner and chief market strategist at Ceri

Jim Lebenthal suggests investing in Qualcomm on CNBC's Halftime Report, while Stephanie Link cho

Dan Deming talks joins today's Big 3 and highlights JPMorgan Chase (JPM) as shares touch new record

FDA approves Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, expandin

Merck wins EU approval for Keytruda plus Padcev in patients with resectable muscle-invasive bladder

U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembr

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United S

This approval is based on results from the pivotal Phase 3 KEYNOTE-905 trial (also known as EV-303),

Merck reported positive Phase 3 data for tulisokibart in ulcerative colitis, meeting primary and key

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced positive top

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced positive top

FDA Expands Merck CAPVAXIVE Use To At-Risk Children And Adolescents Aged 2-17 Following Positive Pha

Expansion to to include children and adolescents aged 2 through 17 years who have completed a primar

Protillion Biosciences, Inc., a leader in lab-in-the-loop AI drug design, today announced the signin

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pembrolizumab

Merck Animal Health has invested in TARGAN since 2017 and has been one of the company's largest

Gilead And Merck Report Phase 3 HIV Trial Success As Separate Lung Cancer Study Of Trodelvy-Keytruda

– Novel Investigational Combination Pairs Merck's Islatravir, a Next-Generation Nucleoside Analo

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (N

https://news.bloomberglaw.com/privacy-and-data-security/merck-to-settle-bulk-of-gardasil-lawsuits-fo

Moderna reports five-year melanoma trial results with Merck and expands its Ebola vaccine partnershi

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study,

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced that calderasib (M

Dell, Qualcomm and HP power an AI-fueled rally to send the Dow to record highs. Nasdaq 100 and S&amp

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the European

A panel of the National Advertising Review Board (NARB), the appellate advertising body of BBB Natio

STELLAR-316 is a planned phase 3 pivotal trial in patients with resected stage II/III colorectal can

https://www.cdc.gov/ebola/situation-summary/index.html

Sac-TMT is the first TROP2 ADC to improve OS and PFS compared to chemotherapy in patients with advan

Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free

Tracey Beth Hoeg was fired as FDA drug division chief amid a broader Trump administration shake-up a

Five-year follow-up data from KEYNOTE-942 underscore the continued potential of intismeran autogene

Inhibrx Biosciences shares rise after Phase 2 INBRX-106 and Keytruda data showed stronger response r

This agreement supports a clinical proof-of-concept study, AURORAS-1, evaluating the pan-RAS molecul